Conflict of Interest/Disclosure Summary: Dr. Pickthorn, Dr. Huang, and Dr. Bell are employees and stockholders of KAI Pharmaceuticals, Inc.
Original Research Article
A Single-Center, Randomized, Double-Blind, Active, and Placebo-Controlled Study of KAI-1678, a Novel PKC-Epsilon Inhibitor, in the Treatment of Acute Postoperative Orthopedic Pain
Article first published online: 8 APR 2013
Wiley Periodicals, Inc
Volume 14, Issue 6, pages 916–924, June 2013
How to Cite
Moodie, J. E., Bisley, E. J., Huang, S., Pickthorn, K. and Bell, G. (2013), A Single-Center, Randomized, Double-Blind, Active, and Placebo-Controlled Study of KAI-1678, a Novel PKC-Epsilon Inhibitor, in the Treatment of Acute Postoperative Orthopedic Pain. Pain Medicine, 14: 916–924. doi: 10.1111/pme.12088
Brief summary of article: Nociceptive properties of protein kinase C (PKC) has been studied for nearly two decades. We found that KAI-1678—a novel inhibitor of epsilon PKC—was not an analgesic for patients with postoperative pain following total hip or total knee replacement surgery. However, a different PKC inhibitor may prove to be a safe and effective analgesic.
- Issue published online: 20 JUN 2013
- Article first published online: 8 APR 2013
Options for accessing this content:
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.